ATE556087T1 - Verfahren zur modulierung des überlebens von zellen, der differenzierung und/oder der synaptischen plastizität - Google Patents

Verfahren zur modulierung des überlebens von zellen, der differenzierung und/oder der synaptischen plastizität

Info

Publication number
ATE556087T1
ATE556087T1 AT04762879T AT04762879T ATE556087T1 AT E556087 T1 ATE556087 T1 AT E556087T1 AT 04762879 T AT04762879 T AT 04762879T AT 04762879 T AT04762879 T AT 04762879T AT E556087 T1 ATE556087 T1 AT E556087T1
Authority
AT
Austria
Prior art keywords
differentiation
ncam
modulating
cell survival
interaction
Prior art date
Application number
AT04762879T
Other languages
English (en)
Inventor
Elisabeth Bock
Vladimir Berezin
Vladyslav Soroka
Christina Kasper
Jensen Kastrup Jette Sandholm
Original Assignee
Enkam Pharmaceuticals As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enkam Pharmaceuticals As filed Critical Enkam Pharmaceuticals As
Application granted granted Critical
Publication of ATE556087T1 publication Critical patent/ATE556087T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
AT04762879T 2003-09-30 2004-09-29 Verfahren zur modulierung des überlebens von zellen, der differenzierung und/oder der synaptischen plastizität ATE556087T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200301418 2003-09-30
PCT/DK2004/000659 WO2005030804A2 (en) 2003-09-30 2004-09-29 A method of modulating cell survival, differentiation and/or synaptic plasticity

Publications (1)

Publication Number Publication Date
ATE556087T1 true ATE556087T1 (de) 2012-05-15

Family

ID=34384509

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04762879T ATE556087T1 (de) 2003-09-30 2004-09-29 Verfahren zur modulierung des überlebens von zellen, der differenzierung und/oder der synaptischen plastizität

Country Status (8)

Country Link
US (1) US7847058B2 (de)
EP (1) EP1678200B1 (de)
JP (1) JP2008501620A (de)
CN (1) CN1886422A (de)
AT (1) ATE556087T1 (de)
AU (1) AU2004275929A1 (de)
CA (1) CA2540644A1 (de)
WO (1) WO2005030804A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008501620A (ja) 2003-09-30 2008-01-24 エンカム ファーマシューティカルズ アクティーゼルスカブ 細胞の生存、分化及び／又はシナプスの可塑性を調整する方法
ES2673872T3 (es) 2012-06-05 2018-06-26 The Board Of Trustees Of The Leland Stanford Junior University Mimético del péptido NCAM para su uso en el tratamiento de trastorno de depresión mayor

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5010175A (en) * 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5840689A (en) * 1993-10-29 1998-11-24 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Method for stimulating the regrowth of neurons
US20020104122A1 (en) * 1994-06-17 2002-08-01 Kirin Beer Kabushiki Kaisha Methods for producing a plant with enhanced resistance to pathogenic fungi
GB9808423D0 (en) 1998-04-22 1998-06-17 Glaxo Group Ltd Bacterial polypeptide family
AU761451B2 (en) * 1998-09-29 2003-06-05 Vladimir Berezin NCAM binding compounds
JP2003525916A (ja) * 1999-04-22 2003-09-02 エイドゲントシッシュ テクニーシェ ホッシュール チューリッヒ モディファイドタンパク質マトリクス
AU6237700A (en) * 1999-07-21 2001-02-13 University Of Massachusetts Kinase blocking polypeptides and uses thereof
WO2002024893A2 (en) * 2000-09-19 2002-03-28 Chiron Corporation CHARACTERIZATION OF THE GSK-3β PROTEIN AND METHODS OF USE THEREOF
US20040242479A1 (en) * 2001-08-17 2004-12-02 Elisabeth Bock Compounds capable of affecting differentiation, proliferation, regeneration, plasticity and survival of cells
AU2003287918A1 (en) * 2002-12-20 2004-07-14 Enkam Pharmaceuticals A/S Method of modulation of interaction between receptor and ligand
EP1660539B1 (de) * 2003-08-07 2010-06-02 Enkam Pharmaceuticals A/S Lpa-haltige verbindungen
JP2008501620A (ja) 2003-09-30 2008-01-24 エンカム ファーマシューティカルズ アクティーゼルスカブ 細胞の生存、分化及び／又はシナプスの可塑性を調整する方法
MXPA06014804A (es) * 2004-06-18 2007-03-23 Enkam Pharmaceuticals As Peptidos de union del receptor del factor de crecimiento fibroblastico.
CA2619017A1 (en) * 2005-08-16 2007-02-22 Copenhagen University Gdnf derived peptides
EP1960425A2 (de) * 2005-11-07 2008-08-27 Copenhagen University Von neurotropien abgeleitete peptidsequenzen
EP2049568A2 (de) * 2006-04-07 2009-04-22 Københavns Universitet Vom erbb-rezeptor abgeleitete peptidfragmente

Also Published As

Publication number Publication date
CA2540644A1 (en) 2005-04-07
EP1678200B1 (de) 2012-05-02
JP2008501620A (ja) 2008-01-24
AU2004275929A1 (en) 2005-04-07
US7847058B2 (en) 2010-12-07
US20080249004A1 (en) 2008-10-09
WO2005030804A2 (en) 2005-04-07
CN1886422A (zh) 2006-12-27
WO2005030804A3 (en) 2005-08-11
EP1678200A2 (de) 2006-07-12

Similar Documents

Publication Publication Date Title
ATE408824T1 (de) Miniaturisierte zellenanordnung und verfahren und vorrichtung zum screening mittels zellen
DE60233574D1 (de) Verfahren und zusammensetzungen zum nachweis des aktivierungszustands multipler proteine in einzelzellen
NO20081013L (no) 7-substituerte aza-indazoler, sammensetninger inneholdende disse, produksjonsmetode og anvendelse derav
ATE389008T1 (de) Verfahren und vorrichtung zum züchten und/oder behandeln von zellen
DK1573323T3 (da) Prion-proteinligander samt fremgangsmåder til anvendelse deraf
DE602006021689D1 (de) Bodenplatte zur Verwendung bei der Massenspektrometrieanalyse sowie Verfahren und Vorrichtung zur Massenspektrometrieanalyse
BRPI0515970A (pt) materiais de ligação de proteìna prìon e métodos de uso
DK1615992T3 (da) Prionproteinbindende materialer og fremgangsmåder til anvendelse
DE602005021327D1 (de) Verfahren, chip, vorrichtung und system zur extraktion biologischer materialien
ATE307902T1 (de) Methoden und testsätze zur probennahme und aufbewahrung von biologischen proben
DE602004020605D1 (de) Verfahren und vorrichtung zur entfernung von organ
DE602005006985D1 (de) Auf produktsezernierung beruhende verfahren zur aufreinigung von zellen
DE502005004900D1 (de) Trägerplatte zur durchführung funktioneller tests an biologischen zellen sowie verfahren zur beschichtung der trägerplatte
DE602006010400D1 (de) Olanzapin-analoga und verfahren zu ihrer verwendung
DE602005008277D1 (de) Von fibrin abgeleitete citrullinpeptide, die durch für rheumatoide arthritis spezifische autoantikörper erkannt werden, und deren verwendung
ATE443296T1 (de) Methoden und system zur identifikation und charakterisierung von peptiden und ihrer funktionellen beziehung mittels berechnung von korrelation
Lorenzo et al. Contrasting complexing capacity of dissolved organic matter produced during the onset, development and decay of a simulated bloom of the marine diatom Skeletonema costatum
ATE551358T1 (de) Verfahren und zusammensetzungen zur modulierung des hepatozytenwachstums, der differenzierung von plasmazellen oder der aktivität von t-zellen durch modulierung der aktivität von xbp-1
ATE540103T1 (de) Verfahren und vorrichtungen zur bearbeitung einzelner biologischer zellen
ATE556087T1 (de) Verfahren zur modulierung des überlebens von zellen, der differenzierung und/oder der synaptischen plastizität
ATE482287T1 (de) Verfahren zum nachweis von aneuploidie unter verwendung eines multiplex- mikropartikelnachweises
ATE340634T1 (de) Verfahren zur verringerung einer adsorptionsneigung von molekülen oder biologischen zellen an einer materialoberfläche
ATE483724T1 (de) Verfahren zur erhöhung der ausbreitung von b- zellen
ATE452984T1 (de) Verfahren und zusammensetzungen zur extraktion von proteinen aus zellen
DK1606622T3 (da) Testfremgangsmåde til bestemmelse af den intracellulære koncentration af cykliske nukleotider